Short answer
Designers developing medical devices or therapeutic interventions for ovarian cancer should consider incorporating VEGF measurement or targeting as a key feature.
- Field
- Innovation & Design
- Source
- Clinical and Experimental Obstetrics & Gynecology (2026)
- Method
- Meta-analysis
- Sample
- 9 studies
- Evidence
- Strong effect
Elevated serum levels of Vascular Endothelial Growth Factor (VEGF) are significantly associated with poorer overall survival in ovarian cancer patients. This innovation & design research insight is drawn from a 2026 study published in Clinical and Experimental Obstetrics & Gynecology. Using Meta-analysis with 9 studies, researchers explored how this design variable affects real-world outcomes. The key design takeaway: Designers developing medical devices or therapeutic interventions for ovarian cancer should consider incorporating VEGF measurement or targeting as a key feature.
Biomarker Elevation in Ovarian Cancer Predicts Poor Prognosis
Elevated serum levels of Vascular Endothelial Growth Factor (VEGF) are significantly associated with poorer overall survival in ovarian cancer patients.
Clinical and Experimental Obstetrics & Gynecology · 2026
Key Findings
- 01Serum VEGF levels were significantly higher in ovarian cancer patients compared to healthy controls.
- 02Serum VEGF levels were higher in patients with advanced-stage ovarian cancer than in early-stage patients.
- 03Serum VEGF levels decreased significantly after surgical treatment.
- 04Elevated serum VEGF levels were significantly associated with poorer overall survival (OS).
- 05The association between serum VEGF levels and disease-free survival (DFS) was not statistically significant.
Application
Design takeaway
Designers developing medical devices or therapeutic interventions for ovarian cancer should consider incorporating VEGF measurement or targeting as a key feature.
How to apply
Incorporate VEGF level assessment into the design of diagnostic assays or as a parameter in predictive models for ovarian cancer.
Project actions
- 01When researching medical conditions, look for established biomarkers that correlate with disease severity or patient outcomes.
- 02Consider how these biomarkers can be integrated into the design of diagnostic tools or treatment plans.
Method & Evidence
Variables
Strengths & Limitations
Strengths
- +Comprehensive literature search across multiple databases.
- +Inclusion of a significant number of studies for robust analysis.
Limitations
This meta-analysis relies on existing studies, and the quality of those original studies can impact the overall findings. The non-significant finding for DFS also suggests further investigation is needed.
Reliability & validity
The reliability of the meta-analysis is enhanced by pooling data from multiple studies. Validity is supported by the significant findings for OS, but the non-significant finding for DFS warrants caution and may indicate limitations in the original studies or the need for more data.
Think critically
How might the variability in measurement techniques for serum VEGF across different studies affect the reliability of this meta-analysis's conclusions?
Design Principles
"Biomarker correlation with disease progression can inform the design of predictive and prognostic tools."
Understanding the relationship between specific biomarkers and disease outcomes is crucial for developing targeted interventions and improving patient care. This insight highlights the potential for VEGF as a predictive indicator in the design of diagnostic tools and therapeutic strategies.
What This Means for Your Design
Measuring a protein called VEGF in the blood can help predict how well someone with ovarian cancer will do.
How to use in your project
- 1.Reference this study when discussing the importance of biomarkers in your design project, especially if your project relates to medical diagnostics or treatment.
Add to My Project
Quick Cite
Paragraph starter
Research indicates that elevated serum VEGF levels are a significant indicator of poorer prognosis in ovarian cancer, with a strong association to overall survival. This suggests that VEGF could serve as a critical biomarker in the design of diagnostic and prognostic tools for this disease, guiding the development of more targeted and effective therapeutic strategies.
Source
Clinical and Experimental Obstetrics & Gynecology
Assessment of Serum VEGF Levels in Ovarian Cancer Prognosis: A Meta-Analysis
journal · 2026
View sourceQuestions About This Research
- What does the research say about biomarker elevation in ovarian cancer predicts poor prognosis?
- Designers developing medical devices or therapeutic interventions for ovarian cancer should consider incorporating VEGF measurement or targeting as a key feature. Evidence: Clinical and Experimental Obstetrics & Gynecology (2026).
- Why does "Biomarker Elevation in Ovarian Cancer Predicts Poor Prognosis" matter for design?
- Understanding the relationship between specific biomarkers and disease outcomes is crucial for developing targeted interventions and improving patient care. This insight highlights the potential for VEGF as a predictive indicator in the design of diagnostic tools and therapeutic strategies.
- How can designers apply this research?
- Designers developing medical devices or therapeutic interventions for ovarian cancer should consider incorporating VEGF measurement or targeting as a key feature.
- What were the main findings?
- Serum VEGF levels were significantly higher in ovarian cancer patients compared to healthy controls.. Serum VEGF levels were higher in patients with advanced-stage ovarian cancer than in early-stage patients.. Serum VEGF levels decreased significantly after surgical treatment.. Elevated serum VEGF levels were significantly associated with poorer overall survival (OS).
- What research method was used?
- Meta-analysis with 9 studies.
- How strong is the evidence?
- Evidence strength is rated Strong effect, based on a 2026 journal from Clinical and Experimental Obstetrics & Gynecology.
- What should I do differently in my next project?
- Incorporate VEGF level assessment into the design of diagnostic assays or as a parameter in predictive models for ovarian cancer.
- What are the limitations?
- The association with disease-free survival was not statistically significant, suggesting a need for further research to clarify its prognostic value.